Genesystem Past Earnings Performance
Past criteria checks 0/6
Genesystem's earnings have been declining at an average annual rate of -285.6%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been declining at an average rate of 78% per year.
Key information
-285.6%
Earnings growth rate
-281.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -78.0% |
| Return on equity | -39.1% |
| Net Margin | -719.2% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Genesystem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,566 | -11,266 | 4,405 | 3,471 |
| 30 Jun 23 | 1,859 | -10,946 | 4,256 | 3,433 |
| 31 Mar 23 | 2,188 | -10,585 | 4,321 | 3,614 |
| 31 Dec 22 | 3,653 | -8,996 | 4,158 | 3,354 |
| 30 Sep 22 | 7,135 | -2,922 | 3,986 | 3,405 |
| 30 Jun 22 | 9,219 | -122 | 3,709 | 3,189 |
| 31 Mar 22 | 12,213 | 2,078 | 3,520 | 3,070 |
| 31 Dec 21 | 13,237 | 3,551 | 3,359 | 2,842 |
| 30 Sep 21 | 12,906 | 1,386 | 4,038 | 2,074 |
| 30 Jun 21 | 14,142 | 2,160 | 4,011 | 2,221 |
| 31 Mar 21 | 13,442 | 173 | 4,020 | 1,887 |
| 31 Dec 20 | 13,258 | -2,224 | 3,821 | 1,631 |
| 31 Dec 19 | 1,135 | -4,041 | 1,502 | 1,199 |
Quality Earnings: A363250 is currently unprofitable.
Growing Profit Margin: A363250 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A363250's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A363250's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A363250 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A363250 has a negative Return on Equity (-39.15%), as it is currently unprofitable.